Code Bio

Code Biotherapeutics develops genetic medicines using its proprietary 3DNA delivery platform, which is designed to improve targeted delivery and reduce toxicity and off-target effects associated with genetic therapies. The company has an internal pipeline focused on rare and prevalent diseases, with its most advanced research in Duchenne Muscular Dystrophy and programs targeting diseases in the lungs, pancreas, and liver.